The company takes stock of the work in the third quarter.
Release time:
2020-07-22
Company takes stock of the work in the third quarter
News from this newspaper 10# June 14 and 15 , the company successively held work analysis meetings in the third quarter of pharmaceutical industry, international trade, cable and cement sectors to summarize the gains and losses of the work in the third quarter and put forward requirements for each business sector to complete the work tasks for the whole year. At the
meeting, the heads of various enterprises made a summary report on the work in the first three quarters, focusing on the comparative analysis of the gains and losses in the third quarter, and put forward ideas for solving problems and improving the work. Chairman Jiang Xiaomeng, General Manager Yu Jianhong and other group company leaders combined with the business data and market trends of each enterprise to comment on the work of each business sector one by one, point out the highlights of the work, analyze the problems and deficiencies, and put forward guidance and requirements on how to better complete the work tasks for the whole year.
In response to recent changes in the pharmaceutical market and management policies, the company requires the pharmaceutical sector to cultivate future comprehensive competitive strength as the top priority of the current work. In terms of research and development, we should strengthen the system construction of scientific research platform, accelerate the adjustment of new drug research and development direction, research and development mode, incentive mechanism, etc., and accelerate the consistency evaluation of existing varieties while searching, introducing and developing new varieties; in terms of industrial sales, we should systematically plan the marketing strategy and promotion of key products, intensively cultivate the basic market, and achieve sales breakthrough; Commercial sales should accelerate transformation and adjustment, good management ideas and methods of "combination boxing " ; Production enterprises should further control production costs on the premise of ensuring quality; Anhui API base and Jinxi internationalization project should do a good job in the construction work at the same time, do a good job in the overall planning of future product introduction and production. The company requires pharmaceutical companies to learn from advanced enterprises and cultivate new ideas to adapt to the new situation of the pharmaceutical industry in the future.
International Trading Company has obtained the qualification of car-free carrier pilot and cotton yarn futures delivery this year, and its business channels have been broadened. The company requires international trading companies to strengthen the standardization and transformation of the park's internal facilities; seriously study and give full play to the operational advantages of the car-free carrier model; further enrich the futures delivery varieties; do more research and investigation, learn from the advanced enterprises of the same industry, and make overall and systematic plans for the future business.
According to the current situation of the cable company, the company requires to further strengthen the quality awareness from the details and control the product quality from the root; carefully study the process and technology of new products, and strengthen the control of each production link; Strengthen equipment maintenance to ensure stable and reliable equipment operation; strengthen staff training, and comprehensively improve staff quality in terms of technical skills, working methods and ideological awareness.
The cement sector has made good profits in recent years. The company requires Daye and Yunnan cement enterprises to firmly establish a sense of crisis, compare advanced indicators in the industry, carefully analyze the deficiencies in management, strengthen equipment management and the investigation and rectification of potential safety hazards, and sort out and implement the on-site work flow strictly according to the standard standards. Improve the staff's business ability and production operation level; Pay special attention to cost control with the attitude of division and competition, do a good job of source management with standards and norms, and do a good job of daily work with the concept of lean production to ensure the competitive advantage of enterprises in order to meet the fierce market competition that is bound to come in the future.
The quarterly analysis meeting of the health products sector was postponed due to work reasons. (this newspaper reporter)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page